Ajay Kshatriya

Ajay Kshatriya is the CEO and co-founder of Aizen Therapeutics, a San Diego biotech that spun out of Caltech to build 'Mirror Peptides' - drugs made entirely of D-amino acids, the mirror image of the proteins nature uses. The company launched from stealth in November 2024 with $13M and a generative-AI platform called DaX. Before Aizen, Ajay founded and ran Biota, an environmental genomics company acquired by Novozymes in 2021 after creating roughly $400M in economic value and saving 1.2 billion gallons of water for industrial clients. A UC Berkeley and Stanford-trained chemical engineer who began his career at Genentech and learned company-building as a seed investor at XSeed Capital, he now also invests in Caltech science startups as a partner at Wilson Hill Ventures.